Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTSH for Adjuvant Diagnosis in Advanced DTC
NCT06431620Recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Jun 2024
- Primary completion
- May 2026
- Modality
- Biologic, rProtein (Recombinant Protein), Hormone
- Countries
- 1
01
Overview
Open-label, single-arm trial of thyrotropin alfa in differentiated thyroid cancer (DTC), sponsored by Nanjing First Hospital. Primary endpoint: Thyroid Stimulating Hormone Level. Started Jun 2024; status: recruiting.
02
Drugs
thyrotropin alfa
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT06431620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06431620.